Edit Target: 285
Ferumoxytol is an intravenous iron replacement product composed of superparamagnetic iron oxide nanoparticles coated with a carbohydrate shell. It was primarily developed to treat iron deficiency anemia, particularly in patients with chronic kidney disease (CKD). The nanoparticle formulation offers both therapeutic iron supplementation and a potential role as a magnetic resonance imaging (MRI) contrast agent because of its unique magnetic properties.
Because iron is essential for cell proliferation, there has been some concern about the theoretical risk of providing additional iron to environments where tumor cells might use it for growth. Nevertheless, the clinical significance of this in the context of ferumoxytol administration remains controversial and is not clearly established by current evidence.
There has been some research combining Ferumoxytol with high dose Vitamin C. Some laboratory studies have examined whether the combination of ferumoxytol and vitamin C can enhance anticancer effects. For instance, exposure of cancer cell lines or tumor models to this combination has been evaluated to see if there is an increase in ROS-mediated cytotoxicity compared to using either agent alone.